Haleon PLC

Haleon PLC’s £65 m Shanghai plant targets China’s tier‑two/three oral‑health boom, using clinical differentiation and local R&D to boost margins and market reach.

Haleon’s debt cut and strong supplement growth give defensive investors a lower‑risk, higher‑yield opportunity in a maturing health‑care market.

Haleon PLC’s debt‑cutting, digital OTC platform, and subscription bundles deliver solid returns, making it a strong defensive investment in a volatile market.

Haleon PLC faces a modest price‑target revision from Berenberg and KPMG, keeping a neutral outlook while urging investors and clinicians to watch upcoming earnings and product updates closely.

Haleon PLC’s strategy to beat regulatory tightening, capitalize on the ageing UK market, and launch a digital wellness platform could boost its 2024 earnings and secure a lead in consumer‑healthcare OTC products.

Haleon PLC’s steady rise in a booming cardiovascular‑health supplement market: evidence‑based trials, regulatory alignment, and investor upside.

Explore Haleon PLC’s latest shareholding shift, new director role, and PDMR policy—why it matters for investors, digital‑health growth, and regulatory compliance.

Haleon names Jon Workman President of European Operations, boosting leadership to strengthen market share, optimize distribution, and accelerate OTC and nutraceutical growth.

Deutsche Bank downgrades Haleon PLC to sell, citing slower earnings and rising costs; other analysts stay neutral, highlighting resilience and potential for strategic moves.

Haleon PLC shows solid financials and steady growth, leveraging strong OTC brands, low payer exposure, and digital strategy to stay resilient amid market volatility.